# An Uncommon Link: Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) in the Setting of Myeloproliferative Neoplasms

**Authors:** Sangya Sharma, Aariez Khalid, Marianne E Yassa, Emad Al Jaber

PMC · DOI: 10.7759/cureus.104231 · Cureus · 2026-02-25

## TL;DR

This paper reports a rare case where a myeloproliferative neoplasm caused inappropriate antidiuretic hormone secretion, leading to long-term low sodium levels.

## Contribution

The paper presents a rare clinical case linking myeloproliferative neoplasms with SIADH and suggests a causal relationship.

## Key findings

- The patient's hyponatremia resolved after treating her myeloproliferative neoplasm.
- A JAK2 V617F mutation was identified, confirming polycythemia vera as the underlying MPN.
- The case suggests a possible causal link between MPNs and SIADH.

## Abstract

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a well-known cause of hyponatremia, frequently associated with small-cell lung carcinoma. Its association with myeloproliferative neoplasms (MPNs), however, is rare and underreported. We describe the case of an 81-year-old female with a history of chronic hyponatremia attributed to SIADH, requiring multiple hospitalizations. During her hospitalizations, she would be on fluid restriction and urea tablets. Her medical history included paroxysmal atrial fibrillation, a stable pulmonary nodule, and seropositive rheumatoid arthritis. Initial hematologic evaluations for cytopenias were unremarkable. Nearly a decade later, she developed pancytosis, and subsequent testing revealed a JAK2 V617F mutation with a 40.1% clone size. A bone marrow biopsy confirmed a diagnosis of polycythemia vera, an MPN. Treatment with intermittent phlebotomy and ruxolitinib led to hematologic improvement and complete normalization of serum sodium levels without the need for continued SIADH-specific therapy. This case highlights a rare but significant association between MPNs and SIADH. Proposed mechanisms include ectopic antidiuretic hormone (ADH) production by malignant cells and microvascular changes promoting ADH release. The resolution of hyponatremia with MPN-directed therapy suggests a causal relationship. Clinicians should consider MPNs in the differential diagnosis of unexplained SIADH. Further research is warranted to elucidate the underlying pathophysiological link.

## Linked entities

- **Genes:** JAK2 (Janus kinase 2) [NCBI Gene 3717]
- **Chemicals:** ruxolitinib (PubChem CID 17754772), urea (PubChem CID 1176)
- **Diseases:** polycythemia vera (MONDO:0009891), rheumatoid arthritis (MONDO:0008383), SIADH (MONDO:0006802), myeloproliferative neoplasms (MONDO:0020076)

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, AVP (arginine vasopressin) [NCBI Gene 551] {aka ADH, ARVP, AVP-NPII, AVRP, VP}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}
- **Diseases:** water retention (MESH:D016055), cytopenias (MESH:D006402), rheumatoid arthritis (MESH:D001172), leukocytosis (MESH:D007964), lung nodule (MESH:D003074), atrial fibrillation (MESH:D001281), chronic thrombocytopenia (MESH:D013921), infection (MESH:D007239), intravascular large B-cell lymphoma (MESH:D016393), thrombocytosis (MESH:D013922), essential thrombocythemia (MESH:D013920), SCLC (MESH:D055752), inflammation (MESH:D007249), pulmonary nodule (MESH:D055613), hyponatremia (MESH:D007010), electrolyte abnormalities (MESH:D014883), edema (MESH:D004487), MPN (MESH:D009369), pulmonary disease (MESH:D008171), multiple myeloma (MESH:D009101), SIADH (MESH:D007177), polycythemia vera (MESH:D011087), renal failure (MESH:D051437), seropositive (MESH:D006679), myelofibrosis (MESH:D055728), volume depletion (MESH:C536350), leukopenia (MESH:D007970), Hypoxia (MESH:D000860), pruritus (MESH:D011537), stem cell disorders (MESH:D000092423), paraneoplastic (MESH:D010257), hematologic malignancies (MESH:D019337), vascular dysregulation (MESH:D021081), AML (MESH:D015470)
- **Chemicals:** Hematoxylin (MESH:D006416), Na (MESH:D012964), hydroxychloroquine (MESH:D006886), H&amp;E (MESH:D006371), urea (MESH:D014508), dupilumab (MESH:C582203), eosin (MESH:D004801), cortisol (MESH:D006854), Eliquis (MESH:C522181), water (MESH:D014867), ruxolitinib (MESH:C540383)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** JAK2 V617F

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12934537/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12934537/full.md

## References

11 references — full list in the complete paper: https://tomesphere.com/paper/PMC12934537/full.md

---
Source: https://tomesphere.com/paper/PMC12934537